Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840914 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
A Phase 1 study of Chronic Heart Failure With Reduced Ejection Fraction, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 7
- Study locations
NCT04840914 is a Phase 1 study of Chronic Heart Failure With Reduced Ejection Fraction that has completed, run by Eli Lilly and Company. The registered enrollment target is 44 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT04840914, a Phase 1 study of Chronic Heart Failure With Reduced Ejection Fraction, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3461767
Study Locations (7)
Michigan
- Henry Ford Hospital - Detroit
Missouri
- Washington University - St Louis
North Carolina
- University of North Carolina, Division of Cardiology - Chapel Hill
Ibaraki
- Tsuchiura Kyodo Hospital - Tsuchiura
Kanagawa
- Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center - Kanazawa Ward,Yokohama
Osaka
- National Cerebral and Cardiovascular Center - Suita-shi
Tokyo
- The University of Tokyo Hospital - Bunkyo-ku
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2024-05-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04840914
The ClinicalTrials.gov registry entry for NCT04840914 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04840914 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Michigan, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04840914 about?
NCT04840914 is a clinical study titled "A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction". The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to ch...
What is the current status of trial NCT04840914?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2021-06-01. Estimated completion is 2024-05-09.
What conditions does trial NCT04840914 study?
This clinical trial studies the following conditions: Chronic Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT04840914?
The interventions under investigation include: Placebo (DRUG), LY3461767 (DRUG).
Who is sponsoring clinical trial NCT04840914?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04840914 being conducted?
This trial has 7 study locations across Michigan, Missouri, North Carolina, Ibaraki, Kanagawa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.